Crossmark

Program death inhibitors in classical Hodgkin’s lymphoma: a comprehensive review

Crossref DOI link: https://doi.org/10.1007/s00277-017-3226-0

Published Online: 2018-01-10

Published Print: 2018-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dada, Reyad https://orcid.org/0000-0002-8221-9342
License Information

Text and Data Mining valid from 2018-01-10

Version of Record valid from 2018-01-10
More Information

Article History

Received: 14 August 2017

Accepted: 27 December 2017

First Online: 10 January 2018

Compliance with ethical standards

:

: The author declares that he has no conflict of interest.